We then used the ATX inhibitor, IOA-289, which is now in Phase 1B trials for the treatment of pancreatic cancer [20], to test if it could attenuate breast tumor growth in the control mice or those with the KO of ATX in adipocytes. Here, ENPP2 is linked to familial pancreatic carcinoma.